Attached To Carbohydrate Compound; Derivative Thereof (e.g., Dna, Nucleotide, Nucleoside, Sugar, Starch, Tannin, Saccharide, Polysaccharide, Cellulose, O-, N- And S-glycoside, Vitamin B12) Patents (Class 424/1.73)
-
Patent number: 8540964Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.Type: GrantFiled: December 8, 2011Date of Patent: September 24, 2013Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
-
Publication number: 20130243692Abstract: This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.Type: ApplicationFiled: May 20, 2013Publication date: September 19, 2013Applicant: Merck Sharp & Dohme Corp.Inventors: Brian Der-Hua Lu, Siu-Long Yao, Cynthia Seidel-Dugan, Yan Wang
-
Patent number: 8524673Abstract: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.Type: GrantFiled: April 21, 2010Date of Patent: September 3, 2013Assignee: KAI Pharmaceuticals, Inc.Inventor: Mike Tso-ping Li
-
Publication number: 20130224113Abstract: The present invention relates to the use of a combination of several contrast agents having different properties with respect to imaging representation.Type: ApplicationFiled: April 11, 2013Publication date: August 29, 2013Applicant: MIVENION GMBHInventor: MIVENION GMBH
-
Patent number: 8512675Abstract: The present invention relates to novel histidine derivates that can be used for the labeling of biomolecules with radioactive metal tricarbonyls. The new derivatives have a histidine that is derivatized at the N? and at least protected at the N? and optionally at the N?; or derivatized at the N? and at least protected at the N? and optionally at the N?; or derivatized at the N? and N? and at least protected at the N? and optionally at the N?; or derivatized at the N?; or derivatized at the N?; or derivatized at the N? and N?; or at least protected at the N? and optionally at the N?.Type: GrantFiled: April 29, 2004Date of Patent: August 20, 2013Assignee: Mallinckrodt LLCInventors: Roger Alberto, Jae Kyoung Pak
-
Patent number: 8501154Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.Type: GrantFiled: September 19, 2012Date of Patent: August 6, 2013Assignee: The Governors of the University of AlbertaInventors: Chris Cheeseman, Frederick West, Tina Grant, Brendan Trayner, John Mercer, Andrei Manolescu
-
Publication number: 20130195756Abstract: An embodiment of the invention comprises a ligand of Formula I wherein R1 and R2 are independently an alkyl or cycloalkyl; R3 is and alkyl; X is CO or SO2; Y is (CH2)n, C6H4, (OCH2CH2)n(NHCH2CH2)n and (OCH2CH2CH2)n, or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10. Also included are an imaging agent comprising a compound of Formula I complexed to 99mTc and their method of use to image a subject having a target site using single photon emission computed tomography (SPECT).Type: ApplicationFiled: January 31, 2012Publication date: August 1, 2013Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Fletcher Johnson, Randall Lee Carter, Michael James Rishel, Mark Christopher Patrick Darey, Tao Wu, Yang Yang, John Fitzmaurice Valliant, Karin Ann Stephenson
-
Publication number: 20130195757Abstract: The invention relates to nucleic acid aptamers having the ability to bind human SPARC protein (osteonectin) with specificity. The invention also relates to compositions including such aptamers, as well as methods of identifying such aptamers. The invention further relates to methods for using such aptamers in treating and diagnosing proliferative diseases such as, e.g., cancer.Type: ApplicationFiled: May 2, 2011Publication date: August 1, 2013Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Kouros Motamed, Yanshan Dai, Vuong Trieu, Neil Desai
-
Patent number: 8496910Abstract: The invention relates to a method for improving stability of radiopharmaceutical precursors, and in particular non radiolabelled nucleoside derivatives which are used as precursors for production of radiolabelled nucleoside derivatives for use in in vivo imaging procedures such as positron emission tomography (PET). The invention further includes formulations of radiopharmaceutical precursors, and cassettes for automated synthesis apparatus comprising the same.Type: GrantFiled: June 20, 2007Date of Patent: July 30, 2013Assignee: GE Healthcare ASInventors: Svein Kvaale, Dirk-Jan In t Veld, Torild Wickstrom
-
Publication number: 20130183238Abstract: A formulation for stabilizing a radiopharmaceutical. The formulation includes a radiopharmaceutical (or a pharmaceutically acceptable salt thereof), a gas which has oxygen, a stabilizer, and a solvent.Type: ApplicationFiled: August 15, 2011Publication date: July 18, 2013Applicant: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Vani P. Mocharla, Fanrong Mu, Umesh B. Gangadharmath
-
Publication number: 20130171065Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.Type: ApplicationFiled: January 29, 2013Publication date: July 4, 2013Applicant: IMMUNOMEDICS, INC.Inventor: Immunomedics, Inc.
-
Patent number: 8475765Abstract: The present invention relates to a method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I) at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II) R?NH—R? (II) wherein R1-R2 and R3 are independently hydrogen or a linear or branched hydroxyalkyl group, and wherein either R? or R? or R? and R? comprise at least one functional group X capable of being reacted with at least one other compound prior to or after the reaction of (I) and (II), as well as to the hydroxyalkyl starch derivative as such, obtainable by said method, and to a pharmaceutical composition comprising said hydroxyalkyl starch derivative.Type: GrantFiled: August 12, 2010Date of Patent: July 2, 2013Assignee: Fresenius Kabi Deutschland GmbHInventors: Norbert Zander, Harald Conradt, Wolfram Eichner
-
Patent number: 8470297Abstract: This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.Type: GrantFiled: September 10, 2010Date of Patent: June 25, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Brian DerHua Lu, Siu-Long Yao, Cynthia Seidel-Dugan, Yan Wang
-
Patent number: 8470295Abstract: A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent.Type: GrantFiled: May 9, 2008Date of Patent: June 25, 2013Assignee: Peak Biosciences, Inc.Inventors: Stephen L. Warren, James E. Matsuura, Michael J. Gerber
-
Publication number: 20130156698Abstract: Methods and compositions related to targeting agents to tumor tissue are described.Type: ApplicationFiled: April 15, 2011Publication date: June 20, 2013Applicant: MOMENTA PHARMACEUTICALS, INC.Inventors: He Zhou, Edward Cochran, Takashi Kei Kishimoto
-
Publication number: 20130149242Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.Type: ApplicationFiled: December 7, 2012Publication date: June 13, 2013Applicant: Ikaria Development Subsidiary One LLCInventor: Ikaria Development Subsidiary One LLC
-
Patent number: 8454936Abstract: Metal chelators of Formula I and Formula II are disclosed: or a pharmaceutically acceptable salt thereof. Also disclosed are metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of their preparation and use in diagnosis and/or treatment of diseases and conditions, including, inter alia, cancer and thrombosis.Type: GrantFiled: April 1, 2010Date of Patent: June 4, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health And Human ServicesInventors: Martin Wade Brechbiel, Thomas Clifford
-
Patent number: 8440243Abstract: A composition comprising various vitamins to make a multi-vitamin. The vitamins identified in multi-vitamin include vitamin B-1, vitamin B-2, niacinamide, vitamin B-6, vitamin B-12, pantothenic acid, folic acid, beta carotene, iron, biotin, choline, vitamin A, vitamin E and vitamin C. The multi-vitamin soothe pain, depression, weakness and insomnia and works best with variety of food and less dairy products. Lead combined with calcium effects are severe than lead effects only; it elevates blood pressure, cholesterol, glucose, weight and cause frequent infections; bigger than normal dose of antibiotics need in infections; and variation in quantities of few vitamins are needed to soothe the symptoms.Type: GrantFiled: July 24, 2008Date of Patent: May 14, 2013Inventor: Renuka Maewal
-
Patent number: 8435491Abstract: A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.Type: GrantFiled: May 13, 2010Date of Patent: May 7, 2013Assignee: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: Mei-Hui Wang, Wuu-Jyh Lin, Chuan-Yi Chien, Hung-Man Yu, Reiko Takasaka Lee, Yuan-Chuan Lee
-
Patent number: 8435792Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.Type: GrantFiled: May 19, 2011Date of Patent: May 7, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger
-
Publication number: 20130101506Abstract: Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds.Type: ApplicationFiled: September 17, 2012Publication date: April 25, 2013Inventor: Cassandra L. Smith
-
Patent number: 8409547Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): R*-L2-C?N+—O???(II) or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: GrantFiled: June 25, 2012Date of Patent: April 2, 2013Assignee: Hammersmith Imanet LimitedInventors: Matthias Eberhard Glaser, Erik Arstad
-
Publication number: 20130078184Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.Type: ApplicationFiled: September 19, 2012Publication date: March 28, 2013Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventors: Chris CHEESEMAN, Frederick WEST, Tina GRANT, Brendan TRAYNER, John MERCER, Andrei MANOLESCU
-
Publication number: 20130071326Abstract: The present invention provides modified stem cells that comprise a delivery system that comprises at least one microparticle or nanoparticle, wherein the at least one microparticle or nanoparticle comprises an active agent. The present invention also provides delivery methods that comprise the administration of the modified stem cells to a subject. Additional aspects of the present invention pertain to methods of making said modified stem cells.Type: ApplicationFiled: March 17, 2011Publication date: March 21, 2013Applicant: Board of Regents of the University of Texas SystemInventors: Jonathan O. Martinez, Ennio Tasciotti, Mikhail Kolonin, Mauro Ferrari
-
Publication number: 20130064767Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.Type: ApplicationFiled: August 28, 2012Publication date: March 14, 2013Applicant: The Johns Hopkins UniversityInventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
-
Publication number: 20130052129Abstract: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.Type: ApplicationFiled: August 27, 2012Publication date: February 28, 2013Applicant: The General Hospital CorporationInventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
-
Patent number: 8383082Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: August 21, 2012Date of Patent: February 26, 2013Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
-
Patent number: 8383083Abstract: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.Type: GrantFiled: June 30, 2011Date of Patent: February 26, 2013Assignee: University of Western OntarioInventors: Duncan H. Hunter, Mustafa Janabi
-
Patent number: 8377418Abstract: The invention relates to a thermosensitive (poly(ethylene oxide) poly(propylene oxide))-acetal derivative, which can be used to functionalize chitosan, and to the process for the preparation thereof. The invention therefore also relates to a process for functionalizing chitosan by grafting this thermosensitive copolymer and optionally another thermosensitive polymer, poly(ethylene oxide). A subject of the invention is also a chitosan-(poly(ethylene oxide) poly(propylene oxide))-poly(ethylene oxide) derivative which has the advantage of being water-soluble at physiological pH. The invention therefore also relates to the aqueous compositions comprising this derivative and to the use of this composition for the manufacture of gel by heating.Type: GrantFiled: September 11, 2008Date of Patent: February 19, 2013Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Joseph Fourier-Grenoble 1Inventors: Rachel Auzely-Velty, Caroline Creuzet
-
Patent number: 8367811Abstract: A radioactive material containing chitosan for inhibiting cancer and a preparation method thereof are revealed. The adioactive material containing chitosan is formed by using SOCTA chelating agent to connect chitosan and radionuclides such as 188Re, and Tc-99m etc. The preparation method of the radioactive material containing chitosan includes the steps of: prepare SOCTA-Chitosan compound; and prepare M(radionuclide)-SOCTA-Chitosan compound. By biocompatibility and clotting in alkaline environment of human blood of chitosan, the radioactive material containing chitosan is injected into cancer and staying there for a long time so as to achieve effectively treatment.Type: GrantFiled: November 3, 2008Date of Patent: February 5, 2013Assignee: Atomic Energy Council-Institute of Nuclear Energy ResearchInventors: Tsai-Yueh Luo, I-Chung Tang, Jian-Wen Chen, Kwei-Luen Hsu, Yu-Lung Wu, Te-Sheng Liang, Chang-Mau Sheng, Jin-Jenn Lin, Ching-Jun Liou, Jyh-Daw Sheu
-
Patent number: 8361439Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: August 20, 2012Date of Patent: January 29, 2013Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Zi-Xian Liao, Ha Giang Thi Nguyen, Er-Yuan Chuang, Hosheng Tu
-
Patent number: 8354093Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.Type: GrantFiled: October 14, 2005Date of Patent: January 15, 2013Assignee: Washington UniversityInventors: Matthew L. Becker, Huafeng Fang, Xiaoxu Li, Dipanjan Pan, Raffaella Rossin, Xiankai Sun, John-Stephen Taylor, Jeffrey L. Turner, Michael John Welch, Karen L. Wooley
-
Patent number: 8354094Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: August 20, 2012Date of Patent: January 15, 2013Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Zi-Xian Liao, Ha Giang Thi Nguyen, Er-Yuan Chuang, Hosheng Tu
-
Patent number: 8343462Abstract: The present invention relates to formulations for use in medical or diagnostic procedures comprising a stabilizing agent alone or in combination with an osmotic agent. In one embodiment, the stabilizing agent is a natural hydrocolloid, preferably locust bean gum, and the osmotic agent is a sugar-based compound, preferably mannitol. The present invention also relates to formulations and methods for distending an anatomic segment. The present invention further relates to formulations and methods for delineating an anatomic segment on a diagnostic image, for example. The formulations of the present invention are especially suitable for use with diagnostic imaging procedures including, but not limited to, magnetic resonance imaging (MR), computer assisted tomography (CT), and CT-PET (position emission tomography), as well as other medical and therapeutic uses.Type: GrantFiled: September 19, 2008Date of Patent: January 1, 2013Assignee: Bracco Diagnostics Inc.Inventors: Thomas C. Lauenstein, Jorg F. Debatin, Hubert Schneemann
-
Patent number: 8337811Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: GrantFiled: March 12, 2012Date of Patent: December 25, 2012Assignees: GP Medical, Inc., National Tsing Hua UniversityInventors: Hsing-Wen Sung, Kiran Sonaje, Ho-Ngoc Nguyen, Er-Yuan Chuang, Hosheng Tu
-
Patent number: 8329141Abstract: The present disclosure provides methods of using unsealed and non-colloidal radiopharmaceuticals, for example beta emitting radiopharmaceuticals such as Yttrium-90 chloride, Indium-111 chloride, F-18-2-deoxy-2-fluoro-D-glucose, or combinations thereof, for locoregional ablation of cells in the abnormal tissue.Type: GrantFiled: March 2, 2007Date of Patent: December 11, 2012Assignee: Board of Regents, The University of Texas SystemInventor: Franklin C. Wong
-
Patent number: 8323617Abstract: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.Type: GrantFiled: June 21, 2011Date of Patent: December 4, 2012Assignee: Anika Therapeutics, Inc.Inventors: Tamera B. Gooding, Stephen J. Kennedy, Charles H. Sherwood
-
Patent number: 8318133Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing compounds as contrast agents. Novel macrocyclic cyanine and indocyanine bioconjugates that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These compounds are especially useful for endoscopic, localized photoacoustic, and sonofluorescence imaging, detection and therapy of tumors and other abnormalities.Type: GrantFiled: November 2, 2010Date of Patent: November 27, 2012Assignee: Washington University in St. LouisInventors: Samuel Achilefu, Yunpeng Ye
-
Patent number: 8317718Abstract: Methods for assessing an overall digestive health of a patient are provided, which include administering a breath test that uses a label incorporated into proteins, carbohydrates, and lipids and further incorporating the labeled material into a meal which, when cooked, facilitates the binding of the label material to the solid phase matrix of the meal. Methods for assessing digestive functions of a patient are also provided, which includes concurrently administering a breath test and a scintigraphy test that measure gastric emptying in a stomach.Type: GrantFiled: May 7, 2008Date of Patent: November 27, 2012Assignee: Advanced Breath Diagnostics, LLCInventors: Kerry C. Bush, Robert F. Martin
-
Patent number: 8313728Abstract: The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.Type: GrantFiled: September 11, 2009Date of Patent: November 20, 2012Assignee: Endocyte, Inc.Inventors: Christopher P. Leamon, Matthew A. Parker
-
Patent number: 8303932Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.Type: GrantFiled: July 12, 2010Date of Patent: November 6, 2012Assignee: Mallinckrodt LLCInventors: Gary L. Cantrell, B. Daniel Burleigh
-
Patent number: 8303934Abstract: A method for the treatment of atherosclerosis. The method includes the administration of a 32P-labeled agent as a beta emitter, such as 32P-labeled ATP or other 32P-labeled adenine nucleotides, whereby the 32P-labeled agent seeks and then permeates the atherosclerotic plaque en bloc without prior degradation. The accumulation of the 32P-labeled agent in the atherosclerotic plaque is achieved at time points whereby the 32P-labeled agent is cleared from the blood. Thus, radionuclide-labeled adenine nucleotides accumulate with high specificity in atherosclerotic lesions and in the heart. The beta particles (electrons) emitted by the 32P-label have a maximal path distance of about 0.5 cm and their energy preferentially destroy cells present in the atherosclerotic plaque without affecting vessel integrity or inducing arterial thrombosis.Type: GrantFiled: July 18, 2011Date of Patent: November 6, 2012Inventor: Eliezer Rapaport
-
Patent number: 8303933Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patient who is then diagnosed or treated using the effector molecule.Type: GrantFiled: July 12, 2010Date of Patent: November 6, 2012Assignee: Mallinckrodt LLCInventors: Gary L. Cantrell, B. Daniel Burleigh
-
Publication number: 20120276005Abstract: Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X1—Y—X2, wherein Y comprises two or more carbohydrate residues covalently attached to one another, X1 and X2 are diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, X1 and X2 are diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.Type: ApplicationFiled: April 3, 2012Publication date: November 1, 2012Inventors: David Yang, Dongfang Yu, Mithu Chanda, Ali Azhdarinia, Changsok Oh, E. Edmund Kim
-
Patent number: 8298582Abstract: A polysaccharide-based solid material including, in its mass, at least one active agent having bactericidal, fungal, insecticidal and/or flame-retardant properties, and at least one complexing agent and/or at least one polymeric matrix having a complexing agent. The active agent includes at least one compound selected from the group including boron, silica, aluminum, phosphorus, iodine, derivatives thereof, aluminosilicate derivatives, and mixtures thereof. The solid material is characterized by an improved stability and by reduced environmental impact, and makes it possible to prepare materials based on wood particles and woods having a particular resistance against environmental attacks such as moisture.Type: GrantFiled: March 28, 2007Date of Patent: October 30, 2012Assignee: Hydro-QuebecInventors: Louis Gastonguay, Michel Perrier, Paul-Étienne Harvey, Jean-François Labrecque, Michel Robitaille, André Besner
-
Publication number: 20120269725Abstract: Method of using androgen receptor and/or butyrylcholinesterase targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for the treatment and diagnosis of cancer.Type: ApplicationFiled: December 23, 2010Publication date: October 25, 2012Inventors: Janine Baranowska-Kortylewicz, Zbigniew P. Kortylewicz
-
Patent number: 8293208Abstract: The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.Type: GrantFiled: May 15, 2009Date of Patent: October 23, 2012Assignee: The Governors of the University of AlbertaInventors: Chris Cheeseman, Frederick West, Tina Grant, Brendan Trayner, John Mercer, Andrei Manolescu
-
Publication number: 20120258043Abstract: Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.Type: ApplicationFiled: April 26, 2012Publication date: October 11, 2012Applicant: BRACCO SUISSE S.A.Inventors: Ramachandran RANGANATHAN, Kondareddiar RAMALINGAM, Radhakrishna PILLAI, Edmund R. MARINELLI, Rolf E. SWENSON
-
Patent number: 8273326Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.Type: GrantFiled: June 20, 2005Date of Patent: September 25, 2012Assignee: The Johns Hopkins UniversityInventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
-
Patent number: 8273719Abstract: An antiwrinkle agent which is highly effective in alleviating wrinkles caused by the photoaging. The present invention relates to an antiwrinkle agent comprising an eugenyl glycoside.Type: GrantFiled: May 14, 2009Date of Patent: September 25, 2012Assignee: Kao CorporationInventors: Takeshi Ikemoto, Aya Komiya, Akinori Haratake